ASX News
Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals
HotCopper sat down with Neurizon Therapeutics MD Michael Thurn to discuss the clinical-stage biotech company's latest NUZ-001 OLE study.
Market Cap $431.0M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| SST | Ann: SST Notice of Change of Australian Registered Office | 19/06/25 | 0 | 167 | |||
|
|||||||
| SST | Ann: SST 2025 AGM Results | 12/06/25 | 0 | 254 | |||
|
|||||||
| SST | Ann: SST Addendum to Notice of 2025 AGM | 15:04 | 0 | 198 | |||
|
|||||||
| SST | Ann: Compliance with Listing Rule 15.1 | 14:46 | 0 | 157 | |||
|
|||||||
| SST | Ann: SST Appendix 3Y Louise M Bromley | 15/05/25 | 0 | 201 | |||
|
|||||||
| SST | Ann: SST Notice of Change of Substantial Shareholding | 15/05/25 | 0 | 191 | |||
|
|||||||
| SST | Ann: SST Notice of 2025 AGM/Proxy Form and Meeting Guide | 09/05/25 | 0 | 266 | |||
|
|||||||
| SST | Ann: SST Corporate Governance Statement 2024 | 30/04/25 | 0 | 184 | |||
|
|||||||
See All Discussions
Timeline
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
| View More | |||||
 (20min delay)
|
|||||
|
Last
$13.90 |
Change
0.000(0.00%) |
Mkt cap ! $431.0M | |||
| Open | High | Low | Value | Volume |
| $13.90 | $13.90 | $13.90 | $14 | 1 |
| SST (ASX) Chart |
